Blue Poppy Enterprises sold herbal products with disease-treatment claims as unapproved new drugs, FDA says.
What happened
FDA reviewed Blue Poppy's websites www.peoplesherbs.com and www.bluepoppy.com, its Amazon Marketplace page, and social media in June and August 2021. FDA found the company took orders for the listed products and made claims that they treat or prevent diseases such as parasites, cancer, allergic rhinitis, herpes simplex, and pain. FDA said the products are unapproved new drugs and some are misbranded for lacking adequate directions for use.
What FDA found
FDA says website and social media claims showed the products were intended to treat, cure, mitigate, or prevent disease, which makes them drugs.
FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]FDA says the products are unapproved new drugs because they are not generally recognized as safe and effective for the claimed uses and lack FDA approval.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]FDA says Modified Perilla & Mentha, Empowered Cordyceps, Empowered Reishi, Sui Bian Guo, and Stop Pain Tincture lack adequate directions for use because they are intended for diseases a layperson cannot safely self-diagnose or treat.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5FDA says introducing or delivering these misbranded drugs into interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Blue Poppy to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations, with an explanation and documentation to prevent recurrence. If corrective actions cannot be completed in that time, the company must state why and give a timeframe; if it believes there is no violation, it must include reasoning and supporting information.
Who should pay attention
- retailers and online marketplaces selling herbal products
- brands that make disease-treatment claims for supplements or topicals
- quality and regulatory teams reviewing website and social media claims
This is a summary. Read the original letter on fda.gov.